Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients.
Natalia JiménezMarta Garcia de HerrerosÒscar ReigMercedes Marín-AguileraCaterina AversaLaura Ferrer-MileoSamuel García-EsteveLeonardo Rodríguez-CarunchioIsabel TriasAlbert FontAlejo Rodriguez-VidaMiguel Ángel ClimentSara CrosIsabel ChirivellaMontserrat DomènechMariona FigolsJoan CarlesCristina SuárezDaniel Herrero RiveraEnrique González-BillalabeitiaClaudia CívicoNúria Sala-GonzálezVicenç Ruiz de PorrasMaria J RibalAleix PratBegoña MelladoPublished in: European urology oncology (2024)
The low RNA expression of tumor suppressor genes in the tumors is correlated with adverse outcomes in patients with metastatic hormone-sensitive prostate cancer.
Keyphrases
- prostate cancer
- gene expression
- radical prostatectomy
- end stage renal disease
- squamous cell carcinoma
- chronic kidney disease
- newly diagnosed
- poor prognosis
- dna methylation
- peritoneal dialysis
- cell proliferation
- genome wide
- patient reported outcomes
- signaling pathway
- long non coding rna
- binding protein
- genome wide identification